Thanks for the hospitality. MD Anderson Cancer Center Very excited for the presentation and also for fruitful discussion with multidisciplinary global experts 👍👍

👏👏Changhoon Yoo, MD giving a Great talk on #BiliaryTractCancers in East Asia MD Anderson Cancer Center Milind Javle Asan Medical Center

No standard therapy after progression on prior IO in uHCC. This single arm phase 2 study showed cabozantinib may be the one of the reasonable options. 👉 sciencedirect.com/science/articl…

Personalized neoantigen vaccine trial in HCC. Huge congrats to Mark Yarchoan

One thing academic oncologists should do is the filling the gaps among the previous trials. We successfully did with mutual trust and excellence in each center. Thanks for the leadership for this project Stephen L. Chan

Worth reminding everyone about D-TORCH study of diclofenac gel in reducing #handfootsyndrome . Simple measures can make chemotherapy tolerable and we should always strive to use them #PROs matter

Ipi/nivo in 1L #HCC is positive! (CheckMate-9DW study). Excited to see the full data soon...
news.bms.com/news/corporate…

In this study, we suggests that monocyte may have key roles in the ICI resistance in uHCC.

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
nature.com/articles/s4158…

Great editorial David James Pinato 🇺🇦

Congratulations to Changhoon Yoo, MD and Hyung-Don Kim for the nice study! Thank u for including our data! Great international #collaboration to advance research in #HCC !

🌟Exciting news! Korean Researchers’ Networking Night at #AACR24 on April 7, 2024 in San Diego! Connect with Korean oncology researchers, build collaborations, and seize networking opportunities. #KSMO_INTL Sign up Today! bit.ly/49newZW

🔥TACE + durvalumab +/- bevacizumab in HCC #GI24
✅ EMERALD-1, 616 pts
👉 ORR: 41 vs 43 vs 29%
👉 mPFS: 15 vs 10 vs 8.2 mo
👉 mOS: too early...
🧐Interesting data, no Durva mono benefit? Bev adds efficacy (again) … Practice changing?
ESMO - Eur. Oncology ILCA EASLnews #livertwitter

Updated results of GALAXY ctDNA cohort were presented today at ASCO GI 2024 Conference. These results will shape the future of colorectal cancer care. #GI24 Natera Oncology

Phase 2 ALPACA #PancreaticCancer #GI24
✅Post 3 x GnP induction
✅ Alternating GnP/Gem vs GnP continuous same OS
➡️ Imp. practical study
➡️ I also like biweekly GnP👇 as shown by Tanios Bekaii-Saab, MD Daniel Ahn

ncbi.nlm.nih.gov/pmc/articles/P…

🎥Changhoon Yoo, MD (@AsanMedicalCtr) shares insights on sequencing therapies in hepatocellular carcinoma at #GI2024 :

➡️ow.ly/i1SH50QsAYC⬅️

ASCO #GIsm #HCCsm OncoAlert

Definitely new first-line option if patients have some tumor burden and financial capacity. Happy to participate in this practice changing trial.

Netter 2 trial indicates markedly superior PFS and response for Lutathera compared to somatostatin analogue therapy in pancreatic and GI grade 2 or 3 pancreatic or GI NET. A new first line option?

New FGFRi in CCA. Promising efficacy even after progression on prior FGFRi. Congrats for study team. Great presentation by Milind Javle